{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Dassau E"],"funding":["Italian Ministero dell’Università e della Ricerca Scientifica","NCATS NIH HHS","National Institute of Diabetes and Digestive and Kidney Diseases","NIDDK NIH HHS","Urdang Family Foundation","National Center for Advancing Translational Science"],"pagination":["1719-1726"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5711334"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["40(12)"],"pubmed_abstract":["<h4>Objective</h4>Artificial pancreas (AP) systems are best positioned for optimal treatment of type 1 diabetes (T1D) and are currently being tested in outpatient clinical trials. Our consortium developed and tested a novel adaptive AP in an outpatient, single-arm, uncontrolled multicenter clinical trial lasting 12 weeks.<h4>Research design and methods</h4>Thirty adults with T1D completed a continuous glucose monitor (CGM)-augmented 1-week sensor-augmented pump (SAP) period. After the AP was started, basal insulin delivery settings used by the AP for initialization were adapted weekly, and carbohydrate ratios were adapted every 4 weeks by an algorithm running on a cloud-based server, with automatic data upload from devices. Adaptations were reviewed by expert study clinicians and patients."],"journal":["Diabetes care"],"pubmed_title":["Twelve-Week 24/7 Ambulatory Artificial Pancreas With Weekly Adaptation of Insulin Delivery Settings: Effect on Hemoglobin A<sub>1c</sub> and Hypoglycemia."],"pmcid":["PMC5711334"],"funding_grant_id":["UL1-TR-000135","Progetto di Ateneo dell’Università di Padova 2014","UL1 TR000135","DP3 DK094331","DP3-DK-094331"],"pubmed_authors":["Bevier WC","Kudva YC","Anderson S","Hinshaw L","Dadlani V","Basu A","Dalla Man C","Patek S","Dassau E","Schiavon M","Hughes J","Church MM","Gondhalekar R","Doyle FJ","Huyett LM","Brown SA","Lv D","Pinsker JE","Dasanayake I","McCrady-Spitzer SK","Carter RE","Cobelli C","Schertz E","Emory E","Bradley PK","Laguna Sanz AJ","Kovatchev B","Jean T"],"additional_accession":[]},"is_claimable":false,"name":"Twelve-Week 24/7 Ambulatory Artificial Pancreas With Weekly Adaptation of Insulin Delivery Settings: Effect on Hemoglobin A<sub>1c</sub> and Hypoglycemia.","description":"<h4>Objective</h4>Artificial pancreas (AP) systems are best positioned for optimal treatment of type 1 diabetes (T1D) and are currently being tested in outpatient clinical trials. Our consortium developed and tested a novel adaptive AP in an outpatient, single-arm, uncontrolled multicenter clinical trial lasting 12 weeks.<h4>Research design and methods</h4>Thirty adults with T1D completed a continuous glucose monitor (CGM)-augmented 1-week sensor-augmented pump (SAP) period. After the AP was started, basal insulin delivery settings used by the AP for initialization were adapted weekly, and carbohydrate ratios were adapted every 4 weeks by an algorithm running on a cloud-based server, with automatic data upload from devices. Adaptations were reviewed by expert study clinicians and patients.","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Dec","modification":"2026-05-02T19:29:52.328Z","creation":"2019-03-27T00:09:16Z"},"accession":"S-EPMC5711334","cross_references":{"pubmed":["29030383"],"doi":["10.2337/dc17-1188"]}}